Navigation Links
Signum Biosciences Names Braham Shroot as Chief Executive Officer
Date:8/5/2010

PRINCETON, N.J., Aug. 5 /PRNewswire/ -- Signum Biosciences, Inc. today announced the appointment of Dr. Braham Shroot, formerly CSO of Barrier Therapeutics, as Chief Executive Officer.  Dr. Shroot replaces Dr. Gregory Stock who will continue to remain active with the Company as a member of the board.

"Braham Shroot brings to Signum an outstanding track record of success in growing value at both start-up and major pharmaceutical companies including Barrier Therapeutics, DFB Bioscience, and Galderma," said Maxwell Stock, President of Signum Biosciences. "We welcome him to the Signum team and look forward to seeing the company progress under his leadership."  

"This is a very exciting time for Signum, with the commercialization of the company's first skin-care compound, Arazine™,  by its partner, Rohto Pharmaceutical in Japan," said Dr. Shroot. "I am equally enthusiastic about Signum's innovative pipeline which holds significant potential to help patients with difficult-to-treat chronic inflammatory and age related pathologies."

Braham Shroot Biography

Braham Shroot is the former CSO of Barrier Therapeutics, Inc., a public dermatology-focused pharmaceutical company, which was acquired by Stiefel Laboratories Inc., in August 2008.  Prior to Barrier, Dr. Shroot was CSO and Vice President of R&D for DFB Pharmaceuticals, Inc., a fully integrated private specialty pharmaceutical company with a focus on skin, wound care, and surgical markets. Before DFB, Dr. Shroot was at L'Oreal where he was G
'/>"/>

SOURCE Signum Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
2. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
3. Pressure BioSciences, Inc. to Discuss Second Quarter 2008 Financial Results and Provide Business Update
4. Milestone Biosciences, LLC Further Strengthens Executive Management Team
5. Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update
6. Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America
7. Pressure BioSciences, Inc. Releases Novel, PCT-dependent Sample Preparation Kit for Systems Biology Studies
8. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
9. Start-Up and Emerging Biotech Companies Will Tell Their Stories at Biosciences Showcase Planned for MichBio Expo
10. Ardea Biosciences to Present Data on Lead MEK inhibitor, RDEA119, at EORTC-NCI-AACR Symposium
11. Pressure BioSciences, Inc. Announces Research Agreement With the US Army Medical Research Institute of Infectious Diseases (USAMRIID)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... DIEGO , April 23, 2015  Neurocrine Biosciences, ... Company will report its first quarter 2015 results before ... Neurocrine will then host a live conference call and webcast ... update Thursday morning, April 30, 2015 at 8:00 a.m. ... can access the live conference call by dialing 866-952-1906 ...
(Date:4/23/2015)... Calif. , April 23, 2015  Veracyte, Inc. (NASDAQ: ... into a definitive agreement to sell approximately $40 million ... the agreement, the investors will purchase an aggregate of ... of $8.15 per share, the closing stock price on ... new and existing investors, including Broadfin Capital, Camber Capital, ...
(Date:4/23/2015)... 23, 2015  Metanome, Inc., an industry leader ... has changed its name to Diversigen, Inc.  The ... the single commercial source for the myriad of ... the diverse opportunities of the microbiome.  From the ... – including those that are difficult to handle, ...
(Date:4/23/2015)... CA (PRWEB) April 23, 2015 Delpor, ... today announced that the United States Patent and Trademark ... Company’s NANOPOR™ technology. US Pat. No. ... Delpor’s microfabricated drug delivery device for the ... proprietary NANOPOR™ technology for the sustained (zero-order) release of ...
Breaking Biology Technology:Neurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2015 Results 2Veracyte, Inc. Announces $40 Million Private Placement 2Veracyte, Inc. Announces $40 Million Private Placement 3Veracyte, Inc. Announces $40 Million Private Placement 4Metanome Announces Corporate Name Change to Diversigen 2Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 2Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 3
... Jan. 7 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ... a research group led,by Dr. Richard Vile ... in Rochester,Minnesota, published the results of its ... various combinations of reovirus and cyclophosphamide in,vivo. ...
... /Xinhua-PRNewswire-FirstCall/ --,Kiwa Bio-Tech Products Group Corporation (KWBT.OB) ... the test results on,Kiwa,s fertilizer products "Pen ... both of,which passed fertilizer sample tests. The ... Amino Acid Leaf Fertilizer,Registration Certificate., In ...
... Jan. 7 DRI Capital (formerly Drug Royalty,Corporation ... investment,strategy and has launched a Structured Finance Fund ... fund is focused on providing,both revenue producing and ... for a variety of uses. The fund represents ...
Cached Biology Technology:Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Cyclophosphamide Treatment 2Kiwa Fertilizers Pass Independent Tests 2Kiwa Fertilizers Pass Independent Tests 3DRI Capital Launches Structured Finance Fund 2
(Date:3/24/2015)... Mar. 24, 2015 Research and Markets ... "Global Iris Recognition Market 2015-2019" report to ... Iris Recognition market to grow at a CAGR of ... report covers the present scenario and the growth prospects ... 2015-2019. To calculate the market size, the report considers ...
(Date:3/24/2015)... , March 24, 2015   Crossmatch ... solutions, today announced that its U.are.U ® ... retailer Goorin Bros . to achieve PCI ... solution secures access to the POS terminal, protecting ... risk of data breaches. With ...
(Date:3/23/2015)... 2015  In the 2014 fiscal year, irs.gov recorded ... This figure accounts for a fraction of the estimated ... Report, exceeds $11 billion globally. The polygraph has traditionally ... has occurred. Investor Mark Saint Juste along ... Paolella partnered to administer the test in a ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... frozen in place frozen solid All of these phrases have ... truth about this southerly point on the globe. Although the ... the most extreme cold on the planet, this ecosystem is dynamic, ... A report published in the March issue of Ecology argues ...
... When scientists around the world think of dung, they think ... University, is one of the world,s foremost authorities on animal ... "You have got to laugh at this bizarre resource," says ... don,t think anyone is keeping track, I suspect we have ...
... a slow-moving mass of cold water that travels south along ... seeing increasing areas of water off Washington and Oregon with ... marine animals that cannot leave the low-oxygen areas. Were ... and far more intense than what has been recorded in ...
Cached Biology News:Antarctic life hung by a thread during ice ages 2Antarctic life hung by a thread during ice ages 3Dung happens and helps scientists 2Dung happens and helps scientists 3Oregon researchers study widespread areas of low oxygen off northwest coast 2
... Blunt-Ended PCR Cloning Kit, 40 reactions. ... cloning of all PCR products with ... cloning approaches by offering consistently better ... 25-fold more positive clones.Amplicons generated by ...
... antibody development to targets including proteins and ... and cancer-specific surface antigens. A&Gs service ... completed in approximately 40 days (duration may ... antigens). Phase I: Immunization, test bleed ...
... ZMD.368. Immunogen: Synthetic peptide derived ... human WNT2B/WNT13 protein. Specificity: Specific ... and rat WNT2B/WNT13 proteins. Recognizes both ... Reactivity: Mouse Human Rat (positive controls: ...
... Immunogen: Synthetic peptide derived from the ... (chromosome 17 open reading frame 37 (C17orf37 ... the C35 protein. On Western blots it ... band. Reactivity: Human (positive control: full-length ...
Biology Products: